Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Dr. Reddy s Laboratories announces launch of India s first DCGI-approved Semaglutide injection Obeda® for Type 2 Diabetes.".
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Reddy's has launched Obeda®, India's first DCGI-approved generic semaglutide injection for Type 2 Diabetes, making it the first Indian company to enter the GLP-1 therapy space on Day 1 of patent expiry. A head-to-head Phase-III study with 312 participants showed non-inferior efficacy and similar safety to the innovator drug (such as Ozempic). The product, available in 2 mg and 4 mg pre-filled pens for once-weekly use, is priced at INR 4,200 per month. The company plans a phase-1 rollout in several other countries and aims to build a full-breadth GLP-1 portfolio covering diabetes and obesity.
This is a significant positive for shareholders, as it gives Dr. Reddy's first-mover advantage in a high-demand segment in India (101 million diabetic adults) and a foothold in the fast-growing global GLP-1 market. The launch could drive meaningful revenue growth, though competition from other generics and pricing pressure remain key risks.